STOCK TITAN
  1. Home
  2. News
  3. OSMT

Osmotica Pharmaceuticals plc to Host UPNEEQ® Overview and Business Update Call on January 19, 2022

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

BRIDGEWATER, N.J., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, announced today that Brian Markison, Chief Executive Officer, James “JD” Schaub, Chief Operating Officer, and other key speakers, will host a call to discuss recent UPNEEQ® trends, pending expansion into the medical Aesthetics market and other general business updates as follows:

Date:Wednesday, January 19, 2022
Time:8:30 a.m. ET
Webcast:https://experience.v-unite.com/#/aestheticrecorddemo/rvlinvestorday/room/welcome

The webcast will be available thereafter via the Company’s website at www.rvlpharma.com under the “Investor & News” section.

About Osmotica Pharmaceuticals plc
Osmotica Pharmaceuticals plc (Nasdaq: OSMT) is a specialty pharmaceutical company focused on the development and commercialization of products that target markets with underserved patient populations. RVL Pharmaceuticals, Inc., is the Company’s ophthalmic and medical aesthetics subsidiary supporting UPNEEQ®.

Investor and Media Relations for Osmotica Pharmaceuticals plc
Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com


Stock OSMT logo
Osmotica Pharmaceuticals Plc

NASDAQ:OSMT

OSMT Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

OSMT Latest News

Jan 19, 2022
UPDATE – Osmotica Pharmaceuticals plc Announces Corporate Name Change to RVL Pharmaceuticals plc, New Ticker Symbol “RVLP,” Plans to Launch UPNEEQ® into the Medical Aesthetics Market, and Provides Fourth Quarter 2022 Net Sales Guidance
Jan 19, 2022
Osmotica Pharmaceuticals plc Announces Corporate Name Change to RVL Pharmaceuticals plc, New Ticker Symbol “RVLP,” Plans to Launch UPNEEQ® into the Medical Aesthetics Market, and Provides Fourth Quarter 2022 Net Sales Guidance
Jan 18, 2022
RVL Pharmaceuticals to Host UPNEEQ® Overview and Business Update Webcast on January 19, 2022
Dec 20, 2021
Osmotica Pharmaceuticals plc to Present at H.C. Wainwright Bioconnect Conference
Nov 15, 2021
Osmotica Pharmaceuticals plc Reports Third Quarter 2021 Results and Provides Business Update

OSMT Stock Data

Medicinal and Botanical Manufacturing
Manufacturing
Link
Health Technology, Pharmaceuticals: Major, Manufacturing, Medicinal and Botanical Manufacturing
US
Bridgewater

About OSMT

Osmotica Pharmaceuticals plc is a fully integrated biopharmaceutical company focused on the development and commercialization of specialty products that target markets with underserved patient populations. The company has a diverse portfolio consisting of promoted and non-promoted products, several of which incorporate Osmotica’s proprietary Osmodex® drug delivery system. RVL Pharmaceuticals, Inc. is the Company’s ophthalmic subsidiary supporting Upneeq®. Vertical Pharmaceuticals, LLC represents the Company’s diversified branded portfolio and Trigen Laboratories, LLC represents the Company’s non-promoted products, including complex generic formulations. Osmotica has operations in the United States, Argentina, and Hungary.